Q1 Earnings Estimate for CRBP Issued By HC Wainwright

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – Investment analysts at HC Wainwright issued their Q1 2025 earnings estimates for Corbus Pharmaceuticals in a research note issued to investors on Thursday, November 7th. HC Wainwright analyst A. Maldonado expects that the biopharmaceutical company will post earnings per share of ($1.33) for the quarter. HC Wainwright has a “Buy” rating and a $80.00 price target on the stock. The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($3.80) per share. HC Wainwright also issued estimates for Corbus Pharmaceuticals’ Q2 2025 earnings at ($1.40) EPS, Q3 2025 earnings at ($1.46) EPS and Q4 2025 earnings at ($1.54) EPS.

Other equities analysts have also issued research reports about the company. Oppenheimer increased their price target on Corbus Pharmaceuticals from $80.00 to $88.00 and gave the company an “outperform” rating in a research report on Wednesday, August 7th. Royal Bank of Canada reissued an “outperform” rating and issued a $82.00 target price on shares of Corbus Pharmaceuticals in a research report on Friday, September 20th. B. Riley reduced their price target on shares of Corbus Pharmaceuticals from $85.00 to $40.00 and set a “buy” rating for the company in a research report on Friday, September 20th. StockNews.com cut shares of Corbus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 10th. Finally, Lifesci Capital upgraded Corbus Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, August 21st. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $65.86.

Corbus Pharmaceuticals Stock Down 3.5 %

CRBP opened at $17.94 on Monday. The firm has a market cap of $216.00 million, a PE ratio of -4.01 and a beta of 2.56. The business has a fifty day simple moving average of $27.47 and a 200-day simple moving average of $41.83. Corbus Pharmaceuticals has a fifty-two week low of $3.03 and a fifty-two week high of $61.90.

Hedge Funds Weigh In On Corbus Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in CRBP. SG Americas Securities LLC bought a new stake in Corbus Pharmaceuticals in the third quarter worth approximately $151,000. Victory Capital Management Inc. increased its position in Corbus Pharmaceuticals by 29.9% during the third quarter. Victory Capital Management Inc. now owns 24,760 shares of the biopharmaceutical company’s stock worth $511,000 after buying an additional 5,700 shares during the last quarter. abrdn plc raised its holdings in Corbus Pharmaceuticals by 422.9% during the third quarter. abrdn plc now owns 26,894 shares of the biopharmaceutical company’s stock valued at $555,000 after buying an additional 21,751 shares in the last quarter. Rhumbline Advisers acquired a new stake in shares of Corbus Pharmaceuticals in the second quarter worth about $638,000. Finally, Acadian Asset Management LLC bought a new stake in shares of Corbus Pharmaceuticals during the 2nd quarter worth about $716,000. Institutional investors and hedge funds own 64.64% of the company’s stock.

Insider Buying and Selling

In other news, major shareholder Cormorant Asset Management, Lp bought 350,000 shares of the company’s stock in a transaction on Friday, September 20th. The shares were bought at an average cost of $20.01 per share, with a total value of $7,003,500.00. Following the transaction, the insider now directly owns 2,375,000 shares in the company, valued at approximately $47,523,750. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 4.00% of the stock is owned by corporate insiders.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.